CDK4/6 Inhibition in the Management of Metastatic HR+/HER2+ Breast Cancer: Systematic Review and Meta-analysis

By afschroeder • January 21, 2026

Park D, Varda M, Yeremian S, Hwang A, Huang C. CDK4/6 Inhibition in the Management of Metastatic HR+/HER2+ Breast Cancer: Systematic Review and Meta-analysis. Target Oncol. 2026 Jan 21. doi: 10.1007/s11523-025-01195-9. Epub ahead of print. PMID: 41559355.

Tags: Fellow, Harbor UCLA, Hematology/Oncology, Publications

Pulmonary Obstruction and Age, Not Activity, Associate With Muscle Oxidative Impairment in Smokers With and Without COPD

Adami A, Duan F, Calmelat RA, Chen Z, Casaburi R, Rossiter HB. Pulmonary Obstruction and Age, Not Activity, Associate With Muscle Oxidative Impairment in Smokers[...]

Trends in Mortality Associated With Ischemic Heart Disease and Screenable Cancers in the United States, 1999 to 2024

Rana JS, Mszar R, Gianos E, Budoff MJ, Nasir K, Ahmed M. Trends in Mortality Associated With Ischemic Heart Disease and Screenable Cancers in the[...]

Symptom status and non-calcified plaque burden across CAC strata: insights from AI-based CCTA quantification

Iskander B, Kambalapalli S, Punnanithinont N, Kinninger A, Krishnan S, Ichikawa K, Lakshmanan S, Roy S, Budoff MJ. Symptom status and non-calcified plaque burden across[...]